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Background. Detection and treatment of latent TB infection (LTBI) in HIV infected individuals is strongly recommended to
decrease morbidity and mortality in countries with high levels of HIV. Objective. To assess the validity of a newly developed
in-house ELISPOT interferon-c release assay (IGRA) for the detection of LTBI amongst HIV infected individuals, in comparison
with the Tuberculin Skin Test (TST). Methodology/Principal Findings. ESAT6/CFP10 (EC) ELISPOT assays were performed,
together with a TST, in 285 HIV infected individuals recruited in HIV clinics in Dakar, Senegal, who had no signs of active TB at
time of enrolment. Thirty eight of the subjects (13.3%) failed to respond to PHA stimulation and were excluded from the
analysis. In the 247 remaining patients, response to PHA did not vary according to CD4 cell count categories (p = 0.51). EC
ELISPOT was positive in 125 (50.6%) subjects, while 53 (21.5%) had a positive TST. Concordance between EC ELISPOT and TST
was observed in 151 patients (61.1%) (kappa = 0.23). The proportion of subjects with a positive response to the EC ELISPOT
assay decreased with declining CD4 counts (p trend= 0.001), but were consistently higher than the proportion of TST
responders. In multivariate analysis, the risk of being EC-ELISPOT positive in HIV infected individuals was associated with age,
CD4 count and HIV-1 strain. Conclusion. Our study indicates that IGRAs using M. tuberculosis specific antigens are likely to
retain their validity for the diagnosis of LTBI among HIV positive individuals, but may be impaired by T-cell anergy in severely
immuno-suppressed individuals.
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INTRODUCTION
Tuberculosis (TB) kills more than twomillion people each year and is
one of the world’s leading causes of death due to infection among
young people and adults [1]. Due to the combined effects of
economic instability, the breakdown of health systems, the spread of
HIV/AIDS and the emergence of multi-drug resistant forms, the TB
burden is increasing in many resource-poor countries. HIV/AIDS
and TB have a deadly synergy, as HIV infection promotes
progression from TB infection to disease [2] and TB accelerates
the course of HIV disease [3]. A recent study in gold-miners in South
Africa showed that the incidence of TB disease doubled within the
first year of HIV seroconversion [4]. Chemoprophylaxis of TB in
HIV infected persons is strongly recommended [5] but the
identification of TB infection in those individuals is difficult. For
many years, latent TB infection (LTBI) has been identified using the
Tuberculin Skin Test (TST), which measures a delayed-type
hypersensitivity response to a purified protein derivative (PPD) of
more than 200 M. tuberculosis (MTB) antigens [6]. Despite its
widespread use, TST unfortunately suffers major limitations due to
cross-reactions with a wide range of environmental mycobacteria
and BCG vaccination, and its sensitivity has been shown to be
substantially reduced in HIV-infected individuals [7].
The characterisation of immunogenic antigens in the Region of
Difference 1 (RD-1), a genomic region present in the M. tuberculosis
complex but deleted from M. bovis BCG and most environmental
mycobacteria, has allowed the development of highly-specific
immuno-diagnostic tests for TB infection [8]. In particular, strong
immune responses to the ESAT-6 and CFP-10 antigens have been
shown to correlate with TB infection, even in asymptomatic
individuals, and several interferon-c release assays (IGRA) have
been developed using these specific antigens [9,10,11]. A number of
studies have showed that IGRAs using ESAT-6/CFP-10 (EC)
antigens were more specific than the TST for the diagnosis of latent
TB infection in endemic settings [11,12]. There is however limited
evidence of the value of these assays among immuno-compromised
individuals, such as those with HIV-infection [13,14]. The
importance of the interaction between HIV and TB urges us to
develop a highly sensitive and specific test for the detection of LTBI
amongst HIV positive patients. The objective of this study was to
investigate, in a high TB prevalent area, the performance of an in-
house enzyme-linked immunospot assay (ELISPOT) measuring
interferon-c release by producing T cells in HIV infected individuals
in different stages of HIV/AIDS progression, and to compare it with
the TST. This study was approved by the Ethics Committee of the
Ministry of Health, Senegal.
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METHODS
The reported HIV seroprevalence in the general population in
Senegal in 2004 was 1.4 % [15]. Approximately 7000 to 8000 new
smear positive TB cases are detected each year and the incidence
rate was estimated at 132 per 100,000 in 2002 [16].
Recruitment of patients took place at the Infectious Disease
Unit and at the Ambulatory Care Centre of Fann Hospital in
Dakar. HIV infected individuals over 18 years of age and living in
Dakar city, presenting with a diagnosis of HIV infection within the
last three months and who had a Karnofsky score of 80 or more
were eligible for the study. Subjects with a diagnosis of TB disease
within the last 12 months, or with clinical, radiological or
mycobacteriological evidence of active TB, as well as those who
had received chemoprophylaxis within the last 6 months, were not
eligible for the study. Eligible patients were informed of the study
protocol and, following discussions in local languages in the
presence of at least two members of the research team and a
witness, gave individual written consent to participate in the study.
All patients were confidentially interviewed and clinically
examined at recruitment. A chest X-ray was performed and blood
samples were collected for full blood count, HIV test, CD4/CD8 cell
count and EC ELISPOT assay. A TST was administrated by the
Mantoux method using 0.1 ml (2 TU) of PPD RT 23 (Statens
Serum Institut, Copenhagen). Tests were read by trained study field
assistants 48–72 hours later and were measured with a ruler as
induration diameters across and along the arm. A mean diameter of
greater than 5 mm was taken as a positive test.
HIV serostatus and serotypes were determined using a serial
algorithm including an enzyme linked immunosorbent assay
(ELISA) (MurexH Ag/Ab, Abbott, Chicago, USA) and an HIV
type 1 and type 2 discriminative test (Innolia, Innogenetics, NV,
Zwjnaarde, Belgium). Relative counts of CD4+ T cells were
determined in EDTA-treated peripheral blood by a direct
immunofluorescence method [17] using a combination of anti-
CD3 peridin chlorophyll protein (PerCP), anti-CD4 fluorescein
isothiocyanate (FITC) and anti-CD8 phycoerythrin (PE) on a
mobile volumetric flow cytometry instrument, the Cyflow SL blue
(Partec GmbH, Mu¨nster, Germany).
The IFN-c ELISPOT assay
The assay was performed on freshly isolated Peripheral Blood
Mononuclear Cells (PBMCs), as previously described [18], predom-
inantly using one pool of 35 15-mer peptides, overlapping by 10
amino-acids (10 mg/ml) and spanning the length of CFP-10 (18
peptides) and ESAT-6 (17 peptides) (Mabtecch AB, Sweden). In a
sub-group of patients, the ESAT-6/CFP-10 (EC) ELISPOT was
performed with four different peptide pools: pool one contained the
first 9 15-mer peptides of ESAT-6 (ES1 to ES9), pool two contained
the last 8 peptides of ESAT-6 (ES10 to ES17), pool three was
composed of the first 9 peptides of CFP-10 (CFP1 to CFP9) and pool
four was composed of the remaining 9 peptides (CFP10 to CFP18).
Briefly, 200,000 PBMCs per well were plated directly onto the
ELISPOT plate (MAIP, Millipore) in the presence of the peptides,
and incubated for 18 hours. PHA (5mg/ml) (Sigma, Missouri, USA)
as positive control and media as negative control, were added to
duplicate wells. ELISPOT plates were counted using an AID plate
reader (Autoimmun Diagnostika, Strassberg, Germany). A positive
response to an antigen pool was taken as more than 20 spot forming
cells (SFC)/106 PBMCafter negative control well SFC subtraction. A
failed positive control was defined as less than 100 spots/106 PBMC
in the phytohaemagglutinin (PHA) positive control wells [19].
The ELISPOT assay was performed using the combined EC
pool in 226 patients. In 45 of them, the test was also performed
using the 4 separate pools. Using Bland and Altman’s method for
assessing agreement between clinical measurements [20], we
observed that the combined pool and the maximum of the 4
separate pools did not appear to agree equally through the range
of the data, with a tendency for mean difference between the two
measurements to rise with increasing response. However, the
variances of the two measurements were not significantly different
(SD combined pool = 169, SD maximum of 4 separate
pools = 152; sd test p= 0.48), which did not suggest that the
observed relationship was a genuine trend [21]. We therefore
included 59 patients whose EC ELISPOT was performed using
the 4 separate pools only. We compared the results of the analysis
which included these 59 patients with the results excluding them
(data not shown) and found that the results were broadly similar
and therefore we report the more complete data.
Statistical Analysis
All data were double entered into an Access database and checked
for errors. Comparisons between the proportions of ELISPOT
positive tests were performed using Fisher’s exact test. Compar-
isons between numbers of SFC according to CD4 absolute count
were performed using non parametric tests (Kruskal-Wallis), with a
significance level of 0.05.
Logistic regression was performed to examine the effect of
potential variables on the odds of presenting a positive ELISPOT
test response. Odds ratios (OR) and their 95% confidence intervals
(CI) were first estimated in a series of univariate analyses. A
multivariate model was then constructed, including variables that
showed an effect in univariate analysis (p,0?2). BCG scar and
gender were forced into the final logistic model. Data were
analysed using STATA 7 software (StataCorp LP, USA).
RESULTS
From October 2003 to March 2005, a total of 298 HIV infected
patients were considered for recruitment. From these, 285 (95.6%)
were enrolled, 2 (0.6%) refused to participate and 11 (3.7%)
presented symptoms and radiological signs for which active TB
could not be excluded, and were therefore not included in the
study. There were no difference in demographic, clinical and
biological characteristics between patients who were included and
those who were not (data not shown). The 285 enrolled HIV
infected patients were 115 males and 170 females and median age
was 37 years (inter-quartile range 30–44) (Table 1). Clinically,
173 (61%) patients were in CDC class B and 212 (74.4%) in WHO
stages I and II. The median CD4 count was 179.5/mm3 (range: 2–
1553). A BCG scar was present in 207 (72.6%) patients, and 60
(21.4%) had a positive TST (.5 mm) at inclusion. Because HIV
infection was recently diagnosed, none of the subjects had received
HAART at the time of inclusion.
The distribution of responses to PHA and to EC ELISPOT
according to CD4 count is shown in Fig 1. Among the 285 HIV
positive patients the median mitogen (PHA) stimulated SFC
response was 543 (range 0–1260) and did not vary according to the
CD4 cell count (p = 0.518) (Fig. 1a). A PHA response inferior to
100 SFC/106 PBMC was however found in 38 (13.3%) patients,
reflecting a failed positive control response. These subjects were
therefore excluded from further analysis. Of note, these subjects
had similar demographic and clinical characteristics as positive
PHA responders (Table 1).
Among the 247 remaining HIV positive patients, the mean
SFC/106 PBMC produced in response to stimulation with EC
antigens was 103 (standard deviation: 186) and the median 22
(range: 0–1247). Using the threshold of 20 SFC/106 PBMC, 125
IFN-c Assay for TB in HIV
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of the 247 (50.6%) subjects had a positive EC ELISPOT response,
while the TST was positive in 53 (21.5%) individuals only.
Concordance between EC ELISPOT and TST was observed in
151 patients (61.1%) (kappa: 0.23). However, 84 (34%) subjects
were EC-ELISPOT positive and TST negative, while 12 (4.9%)
were TST positive and EC-ELISPOT negative. The relative
proportion of positive responses with each test did not change
significantly when using cut-offs of 10 SFC/106 or 30 SFC/106
(data not shown).
The mean total lymphocyte count was similar in HIV infected
patients who showed a positive response to EC-ELISPOT (38%) and
those who did not (37%), and the median EC stimulated SFC did not
vary according to the CD4 cell count (p=0.3) (Fig. 1b). However,
the proportion of positive responses to the EC ELISPOT assay
decreased with decreasing CD4 counts (test for trend: p=0.0012)
(Fig 2), and for all categories of CD4 count, the proportion of
responders to EC ELISPOT was consistently higher than the pro-
portion of TST responders. Of note, the proportion of patients with a
BCG scar was distributed evenly across the CD4 count categories.
We examined the effect of given demographic and clinical factors
on the likelihood of developing a positive response to the EC
ELISPOT assay as well as to the TST (Table 2). This analysis
confirms the effect of CD4 cell count on the risk of positive EC
ELISPOT and TST responses (p=0.016 and p,0.0001 respective-
ly). Positive responses to EC ELISPOT were associated with age,
conversely to TST positivity, but not with sex or family history of TB.
EC ELISPOT positivity was associated with HIV1 infection, but not
with the clinical severity of disease, as assessed through CDC
classification. As expected, the presence of a BCG scar had an effect
on TST positivity, but not on EC ELISPOT positivity.
DISCUSSION
The identification and treatment of latent TB infection (LTBI) in
HIV positive individuals is one of the main recommendations
developed by the World Health Organisation in order to reduce
morbidity and mortality in HIV patients living in high TB
prevalence areas [5]. Tuberculin skin testing has been shown to be
Table 1. Characteristics of patients included in the cohort,
with a detail of those responding and those not responding
to ELISPOT PHA positive control.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Characteristics
All Patients
(n = 285)
PHA,100 SFC/
106 (n = 38)
PHA$100 SFC/
106 (n = 247) p-value*
Number (%) Number (%) Number (%)
Gender
- male 115 (40.4) 14 (36.8) 101 (40?9)
- female 170 (59.6) 24 (63.2) 146 (59?1) 0.72
Age (years)
- ,30 55 (19.3) 6 (15.8) 49 (19?8)
- 30–39 112 (39.3) 15 (39.5) 97 (39?2)
- 40–49 86 (30.2) 12 (31.6) 74 (30?0)
- $50 32 (11.2) 5 (13.2) 27 (10?9) 0.92
CDC classification
- A 94 (33.0) 11 (29.0) 83 (33?6)
- B 173 (60.7) 25 (65.8) 148 (59.9)
- C 18 (6.3) 2 (5.3) 16 (6.5) 0.88
WHO classification
- I 89 (31.2) 10 (26.3) 79 (32.0)
- II 123 (43.2) 19 (50.0) 104 (42.1)
- III 60 (21.1) 7 (18.4) 53 (21.5)
- IV 13 (4.5) 2 (5.3) 11 (4.4) 0.78
BCG scar
- Yes 207 (72.6) 31 (81.6) 176 (71?3)
- No 78 (27.4) 7 (18.4) 71 (28?7) 0.24
TST (mm)
- 0–5 224 (78.6) 30 (79.0) 194 (78?5) 0.95
- .5 61 (21.4) 8 (21) 53 (21?5)
CD4 count (per mm3)
- ,50 58 (20.3) 6 (15.8) 52 (21?0)
- 50–199 88 (30.9) 12 (31.6) 76 (30?1)
- 200–349 43 (15.1) 10 (26.3) 33 (13?4)
- $350 85 (29.8) 8 (21) 77 (31?2)
- undetermined 11 (3.9) 2 (5?3) 9 (3?6) 0.95
Haemoglobin level (g/dl)
- ,10 g/dl 141 (49.5) 17 (44.7) 124 (50?2)
- $10 g/dl 128 (44.9) 19 (50.0) 109 (44?1)
- undetermined 16 (5.6) 2 (5?3) 14 (5?6) 0.59
*p value for difference between PHA,100 and PHA$100 SFC/106.
doi:10.1371/journal.pone.0001441.t001..
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Figure 1. Distribution of responses to PHA and ESAT6/CFP10 ELISPOT
assays in HIV patients, by CD4 cell count (boxplot showing median,
IQR and range) (n = 285). 1A: Distribution of responses to PHA. 1B:
Distribution of responses to ESAT6/CFP10.
doi:10.1371/journal.pone.0001441.g001
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highly inadequate for identifying LTBI in HIV infected individuals,
as the anergy to skin testing may lead to false negative results [7].
More sensitive and specific diagnostic tools are therefore urgently
required [22,23]. We report here the results from a study comparing
an in-house ESAT-6/CFP-10 (EC) assay with TST for the diagnosis
of LTBI in an HIV infected cohort in a TB endemic country. Our
study showed that, similar to findings in HIV negative cohorts
[11,24,25], the EC-ELISPOT assay appears more sensitive than the
TST in HIV infected individuals, but this sensitivity appears
impaired in those with severe immuno-suppression.
The sensitivity and specificity of a new diagnostic test is usually
assessed through comparison with a gold standard diagnostic
assay. While the gold standard for TB disease is the positive culture
of M. tuberculosis, there is no such standard for TB infection.
However, given that TB disease is highly prevalent in HIV patients
[2] and that the TST has a high false negative rate for the diagnosis
of TB disease in these patients, the increased frequency of positive
responses to the EC-ELISPOT in HIV patients when compared to
the TST is likely to reflect an increased sensitivity of the former. To
our knowledge, this is the largest study reporting such results in a
high TB prevalent country affected with HIV infection.
The recent breakthrough brought about by the development of
TB specific T-cell based IGRA has raised high hopes for an
improved diagnosis of LTBI, with an expectedly wide impact on
TB control. IGRA do indeed carry several advantages over the
century old TST [26]: testing requires only 1 patient visit and as
these are ex-vivo tests, the risk for adverse effects is reduced and
potential boosting is eliminated when testing is repeated. However,
IGRAs are costly, impose blood drawing, and necessitate
appropriately equipped laboratory. In addition, samples need to
be carefully handled to maintain viability of lymphocytes. Current
evidence suggests that IGRA have higher specificity than the TST,
better correlation with surrogate markers of exposure to M.
tuberculosis in low-incidence settings, and less cross-reactivity to
BCG vaccination than the TST [26,27].
In HIV infected persons, there is a concern that, similarly to the
TST [28], the performance of the test could be impaired due to
anergy associated with decreasing CD4 cell counts resulting in false
negative ELISPOT responses [26]. The performance of whole-blood
cytokine assays for the diagnosis of LTBI in HIV positive versus
HIV-negative patients has previously been assessed in two small
studies in Africa, with conflicting results. In a study in Uganda, Elliot
et al found that the IFN-c response to PPD and CFP-10 antigens was
strongly impaired among HIV positive compared to HIV negative
subjects [13]. In contrast, in a study conducted in Zambia, the
sensitivity of the ELISPOT assay (using PPD and ESAT-6 or CFP-10
antigens) was only slightly reduced in HIV positive patients (90%), as
opposed to HIV negative patients (100%) [14].
There are very few reports on the performance of IGRAs
according to the degree of immuno-suppression. Many laborato-
ries use PHA stimulation as a positive control in cellular assays,
such as the ELISPOT. To assess the utility of IGRAs in immuno-
suppressed individuals, authors have examined whether responses
to PHA decrease with CD4 T cell count. In a study assessing
response to M. tuberculosis specific antigens among 590 HIV
positive patients in Denmark using the Quantiferon-TB In Tube
test, the proportion of patients with indeterminate test results due
to low IFN-c production following PHA stimulation was
significantly higher in patients with low CD4 count (,100 cells/
ml) compared to those with high CD4 cell count (. 100 cells/ml),
and the median IFN-c release was significantly lower in those
persons with a low CD4 cell count compared with patients with a
high CD4 cell count [29]. However, we and others have shown
that, when using the ELISPOT assay, the PHA response did not
vary with CD4 cell count [19,30]. In the ELISPOT assay, PBMCs
are isolated and counted, and known numbers of cells are added
into each well. Therefore, as the CD4 cell count falls, more
PBMCs are added into the ELISPOT assay to compensate this
fall, and the PHA response is maintained. In our study, in all CD4
count classes, the EC ELISPOT showed consistently improved
sensitivity over the TST. However, despite a maintained PHA
response, the proportion of patients with a positive response to the
EC ELISPOT decreased with the CD4 cell count, and this was
particularly marked in severely immuno-suppressed individuals
Figure 2. Percentage of positive responders to ESAT6/CFP10 ELISPOT and to TST, by CD4 cell count (n = 247).
doi:10.1371/journal.pone.0001441.g002
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The low proportion of positive responses to the EC-ELISPOT in
HIV infected person with CD4 cell counts lower than 200/mm3,
and particularly among those with less than 50/mm3, could either
reflect a smaller proportion of patients being infected with M.
tuberculosis in that group of subjects, or more likely, the suppression of
the antigen-specific M. tuberculosis T cell response with the
progression of HIV infection, as has been shown by Sutherland et
al. in chronic HIV-1 infected persons [31]. Altogether, our results
confirm the findings by Chapman et al of a higher sensitivity of the
EC-ELISPOT assay compared to TST for the diagnosis of LTBI in
HIV infected individuals [14], but also suggest that the sensitivity of
this test be dependant on HIV progression. Thus, IGRA assays
appear very useful for the diagnosis of LTBI in HIV infected
individuals, with an increased performance compared with the TST,
but in severely immuno-suppressed individuals, the test may be
impaired by T-cell anergy, warranting a careful interpretation of
negative results in these patients.
The multivariate analysis showed that the positive response to
EC-ELISPOT assay was associated with age, CD4 count and
HIV-1 strain. The EC-ELISPOT was more likely to be positive in
individuals aged more than 50 years, which may reflect repeated
exposure to TB infection that would occur during the lifetime in
an endemic setting. It has previously been shown that TST
positivity increased with age in an HIV negative cohort [32]. The
lack of association between TST and age in our study may be due
to the strong impact of HIV infection on TST and the high level of
TST anergy observed. The moderate effect seen in the older age
group is in favour of increased sensitivity of the EC ELISPOT in
comparison with the TST in this HIV infected population.
The difference of effect observed with the HIV type may be
related to epidemiological and biological differences. While HIV-1
is found across the globe, HIV-2 is confined mainly to West Africa.
Rates of disease progression are, however, significantly lower in
HIV-2 infection when compared to HIV-1 [33] and as TB disease
is associated with increased HIV progression it is not surprising
that in our study TB infection is associated with HIV-1 strain.
In conclusion, this study showed that the EC IFN-c release assay
is likely to retain its validity for the diagnosis of LTBI among HIV
positive patients, with the caveat that its sensitivity decreases with
advanced immuno-suppression. Establishing the critical level of
immuno-suppression under which the performance of the IGRA
may be improved (i.e. determining the critical CD4 cut-off) is now
a priority. This will enable this new T cell based test to contribute
usefully to the diagnosis of LTBI in HIV infected persons and
would usefully contribute to TB control by improving the direction
of preventive therapy among HIV positive patients.
Table 2. Analysis of the determinants of positive response to the ESAT6/CFP10 ELISPOT assay and to the TST (n = 247).
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Variables N TST positive response EC Elispot positive response
Univariate OR
[95% CI] p
Adjusted OR
[95% CI] p
Univariate OR
[95% CI] p
Adjusted OR
[95% CI] p
CD4 class
- ,50 52 1 1 1 1
- 50–199 76 8.1 [1.0–64.9] 8.5 [1.0–69] 1.7 [0.8–3.5] 1.5 [0.7–3.2]
- 200–349 33 17.3 [2.1–141] 14.8 [1.7–129] 2.9 [1.2–7.2] 2.7 [1.1–7.1]
- $350 77 46.1 [6.1–348] 36.6 [4.6–288] 3.1 [1.5–6.5] 3.2 [1.5–7.0]
- undetermined 9 5.7 [0.3–98] 0.0001 5.5 [0.3–97] 0.0001 0.9 [0.2–4.2] 0.018 0.7 [0.1–3.8] 0.016
HIV type
- HIV 1 - dually infected 216 1 - - 1 1 0.02
- HIV 2 32 0.64 [0.3–1.4] 0.27 0.4 [0.2–0.9] 0.03 0.3 [0.1–0.8]
CDC class
- A 83 1 1 1 - -
- B or C 164 1.9 [1.1–3.3] 0.03 1.11 [0.5–2.2] 0.5 1.2 [0.7–2.0] 0.59
Age (years)
- ,30 49 1 1 1 1
- 30–39 97 1.2 [0.5–2.6] 1.0 [0.4–2.7] 0.9 [0.5–1.8] 0.9 [0.4–1.9]
- 40–49 74 1.3 [0.5–3.0] 1.3 [0.4–3.7] 0.7 [0.3–1.5] 0.8 [0.4–1.8]
- $50 27 1.7 [0.6–4.9] 0.74 1.7 [0.5–6.1] 0.78 5.0 [1.5–16.9] 0.016 4.3 [1.3–13.6] 0.024
Gender
- Male 101 1 1 1 1
- Female 146 0.7 [0.4–1.3] 0.32 0.8 [0.5–1.3] 0.8 [0.5–1.3] 0.45 0.7 [0.4–1.3] 0.26
BCG scar
- No 71 1 1 1 1
- Yes 176 3.6 [1.5–8.3] 0.003 3.3 [1.2–8.6] 0.01 1.1 [0.6–2.0] 0.41 1.1 [0.6–2.0] 0.75
Family history of TB
- No 239 1 - - 1 - -
- Yes 8 2.3 [0.5–9.8] 0.26 2.7 [0.5–20.1] 0.27
doi:10.1371/journal.pone.0001441.t002..
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